News
BCTXZ
0.2800
0.00%
0.00
BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting
Barchart · 1d ago
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
Barchart · 08/05 06:30
BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™
Barchart · 07/15 06:30
BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™
Barchart · 07/07 06:30
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
Barchart · 06/25 06:30
BriaCell Therapeutics Announces Closing of Offering
Barchart · 06/02 15:05
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
Barchart · 05/26 06:30
BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026
Barchart · 05/22 06:30
BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
Barchart · 05/15 06:30
BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
Barchart · 05/14 06:30
BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
Barchart · 05/12 06:30
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
Barchart · 04/27 06:30
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
Barchart · 04/21 06:30
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
Barchart · 04/20 06:30
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting
Barchart · 03/10 06:30
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License
Barchart · 02/18 16:30
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
Barchart · 02/17 06:30
BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
Barchart · 01/27 06:30
BriaCell Therapeutics Announces Pricing of $30 million Public Offering
Barchart · 01/13 20:00
BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
Barchart · 12/10/2025 06:30
More
Webull provides a variety of real-time BCTXZ stock news. You can receive the latest news about Briacell Therapeutics Corp through multiple platforms. This information may help you make smarter investment decisions.